Insulet and Dexcom Agree to Develop a CGM-Integrated Personal Diabetes Manager

Insulet and Dexcom Agree to Develop a CGM-Integrated Personal Diabetes Manager 
New Insulet PDM Will Receive Dexcom G5 CGM Sensor Signals 
BEDFORD, MA -- (Marketwired) -- 08/05/14 --  Insulet Corporation
(NASDAQ: PODD), the leader in tubeless insulin pump technology with
its OmniPod(R) Insulin Management System, and DexCom, Inc (NASDAQ:
DXCM), the leader in continuous glucose monitoring ("CGM")
technology, today announced their intention to allow information from
Dexcom's 5th generation CGM system to be identified, received and
displayed on Insulet's new Bluetooth-enabled Personal Diabetes
Manager ("PDM"), currently in development.  
This project expands upon the initial agreement announced in June to
enable the Dexcom mobile app platform to integrate data from
Insulet's OmniPod System. That platform will be the first of its kind
to enable glucose and pump data to be displayed on a smartphone.  
"We are pleased to expand our development relationship with Dexcom to
receive and display Dexcom G5 Sensor data on our new PDM, eliminating
the need to carry a separate CGM receiver," said Duane DeSisto,
President and Chief Executive Officer of Insulet. "This collaboration
furthers our shared vision of helping people living with diabetes by
providing greater access to the data they need to make smart and
effective decisions to better manage and control their disease." 
"We are pleased to be back working with Insulet to bring our
leading-edge technologies together to help people living with
diabetes better manage their disease," said Kevin Sayer, President
and Chief Operating Officer of Dexcom.  
About Insulet Corporation 
 Insulet Corporation (NASDAQ: PODD) is an
innovative medical device company dedicated to making the lives of
people with diabetes easier. Through its OmniPod Insulin Management
System, Insulet seeks to expand the use of insulin pump therapy among
people with insulin-dependent diabetes. The OmniPod is a
revolutionary and easy-to-use tubeless insulin pump that features
just two parts and fully-automated cannula insertion. Insulet's
subsidiary, Neighborhood Diabetes, is a leading distributor for
diabetes products and supplies, delivered through a high touch
customer service model. To read inspiring stories of people with
diabetes living their lives to the fullest with OmniPod, visit our
customer blog, Suite D: Founded in 2000,
Insulet Corporation is based in Bedford, Mass. For more information,
please visit:  
About DexCom, Inc.
 DexCom, Inc. (, headquartered in
San Diego, California, is developing and marketing continuous glucose
monitoring systems for ambulatory use by patients and by healthcare
providers in the hospital.  
DexCom's Cautionary Statement Regarding Forward Looking Statements  
Dexcom is a medical device company with a limited operating history.
Successful commercialization of the company's products is subject to
numerous risks and uncertainties, including a lack of acceptance in
the marketplace by physicians and patients, the inability to
manufacture products in commercial quantities at an acceptable cost,
possible delays in the company's development programs, the inability
of patients to receive reimbursement from third-party payors and
inadequate financial and other resources. Certain of these risks and
uncertainties, in addition to other risks, are more fully described
in the company's quarterly report on Form 10-Q for the period ending
March 31, 2014, as filed with the Securities and Exchange Commission
on May 1, 2014. 
Insulet's Cautionary Statement Regarding Forward Looking Statements 
This press release contains forward-looking statements concerning
Insulet's expectations, anticipations, intentions, beliefs or
strategies regarding the future, including those related to future
product development. These forward-looking statements are based on
its current expectations and beliefs concerning future developments
and their potential effects on Insulet. There can be no assurance
that future developments affecting Insulet will be those that it has
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or other
assumptions that may cause actual results or performance to be
materially different from those expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to: risks associated with the Company's
dependence on its principal product, the OmniPod System;
technological change and product innovation adversely affecting the
Company's business; potential termination of Insulet's license to
incorporate a blood glucose meter into the OmniPod System or its
inability to enter into new license agreements; Insulet's ability to
protect its intellectual property and other proprietary rights;
conflicts with the intellectual property of third parties, including
claims that Insulet's current or future products infringe or
misappropriate the proprietary rights of others; adverse regulatory
or legal actions relating to the OmniPod System; the potential
violation of federal or state laws protecting the confidentiality of
patient health information, or any challenge to or investigation into
Insulet's practices under these laws; product liability lawsuits that
may be brought against Insulet; and other risks and uncertainties
described in its Annual Report on Form 10-K, which was filed with the
Securities and Exchange Commission on February 28, 2014 in the
section entitled "Risk Factors," and in its other filings from time
to time with the Securities and Exchange Commission. Should one or
more of these risks or uncertainties materialize, or should any of
its assumptions prove incorrect, actual results may vary in material
respects from those projected in these forward-looking statements.
Insulet undertakes no obligation to publicly update or revise any
forward-looking statements. 
Investor Relations Contact: 
877-PODD-IR1 (877-763-3471) 
Press spacebar to pause and continue. Press esc to stop.